ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Maan, Raoel ^a   Van Der Meer, Adriaan J ^a   Brouwer, Willem Pieter ^a   Plompen, Elisabeth P C ^a   Sonneveld, Milan J ^a   Roomer, Robert ^a   Van Der Eijk, Annemiek A ^a   Groothuismink, Zwier M A ^a   Hansen, Bettina E ^a   Veldt, Bart J ^a   Janssen, Harry L A ^a,b   Boonstra, Andre ^a   De Knegt, Robert J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; ANTIVIRUS AGENT; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BLOOD TRANSFUSION; CAUCASIAN; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; ENZYME ACTIVITY; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; INOSINE TRIPHOSPHATE PYROPHOSPHATASE DEFICIENCY; ITPA GENE; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; GENETIC POLYMORPHISM; GENETICS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; STATISTICAL MODEL;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEMOGLOBINS; HEPATITIS C, CHRONIC; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET COUNT; POLYMORPHISM, GENETIC; PYROPHOSPHATASES;

EID: 84947776269     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0139317     Document Type: Article

References (37)

1. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. N Engl J Med. 2014. Epub 2014/04/15. doi: 10.1056/NEJMoa1402454 PMID: 24725239.
2. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV. N Engl J Med. 2014. Epub 2014/05/06. doi: 10.1056/NEJMoa1402338 PMID: 24795200.
3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl 1):S237-44. Epub 2002/10/31. S0270913902001945 [pii] doi: 10.1053/jhep.2002.36810 PMID: 12407599.
4. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis C. Gastroenterology. 2003; 124 (6):1711-9. Epub 2003/05/23. S0016508503003949 [pii]. PMID: 12761728.
5. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002; 123(4):1061-9. Epub 2002/10/03. S0016508502002111 [pii]. PMID: 12360468.
6. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology. 2007; 132(1):103-12. Epub 2007/01/24. S0016-5085(06)02466-8 [pii] doi: 10.1053/j.gastro.2006.11.011 PMID: 17241864.
7. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010; 464(7287):405-8. Epub 2010/02/23. nature08825 [pii] doi: 10.1038/nature08825 PMID: 20173735.
8. Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology. 2011; 140(4):1314-21. Epub 2011/01/05. S0016-5085(10)01883-4 [pii] doi: 10.1053/j.gastro.2010.12.038 PMID: 21199653.
9. Rembeck K, Waldenstrom J, Hellstrand K, Nilsson S, Nystrom K, Martner A, et al. Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology. 2014; 59(6):2131-9. Epub 2014/02/13. doi: 10.1002/hep.27009 PMID: 24519039.
10. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012; 56(2):313-9. Epub 2011/06/28. S0168-8278(11)00385-0 [pii] doi: 10.1016/j.jhep.2011.04.021 PMID: 21703177; PubMed Central PMCID: PMC3634361.
11. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995; 85(7):1719-26. Epub 1995/04/01. PMID: 7535585.
12. Cardier JE, Erickson-Miller CL, Murphy MJ Jr. Differential effect of erythropoietin and GM-CSF on megakaryocytopoiesis from primitive bone marrow cells in serum-free conditions. Stem Cells. 1997; 15 (4):286-90. Epub 1997/01/01. doi: 10.1002/stem.150286 PMID: 9253112.
13. Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, et al. ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response. Hepatology. 2014; 59(6):2152-60. Epub 2014/01/23. doi: 10.1002/hep.27022 PMID: 24449403.
14. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2011; 53(2):389-95. Epub 2011/01/29. doi: 10.1002/hep.24068 PMID: 21274861.
15. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol. 2010; 53(3):455-9. Epub 2010/06/22. S0168-8278(10)00470-8 [pii] doi: 10.1016/j.jhep.2010.04.013 PMID: 20561709.
16. Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010; 52(4):1225-31. Epub 2010/09/11. doi: 10.1002/hep.23842 PMID: 20830784.
17. Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, et al. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat. 2013; 20(12):858-66. Epub 2013/12/07. doi: 10.1111/jvh.12113 PMID: 24304455.
18. European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014; 61(2):373-95. Epub 2014/05/14. S0168-8278(14)00309-2 [pii] doi: 10.1016/j.jhep.2014.05.001 PMID: 24818984.
19. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. Epub 2009/08/18. nature08309 [pii] doi: 10.1038/nature08309 PMID: 19684573.
20. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011; 54(3):415-21. Epub 2010/11/30. S0168-8278(10)00834-2 [pii] doi: 10.1016/j.jhep.2010.07.041 PMID: 21112657.
21. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. Epub 2009/09/15. ng.447 [pii] doi: 10.1038/ng.447 PMID: 19749758.
22. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009; 169(4):505-14. Epub 2009/01/08. kwn359 [pii] doi: 10.1093/aje/kwn359 PMID: 19126586; PubMed Central PMCID: PMC2640163.
23. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem. 2006; 52(2):240-7. Epub 2005/12/31. clinchem.2005.059501 [pii] doi: 10.1373/clinchem.2005.059501 PMID: 16384889.
24. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet. 2002; 111(4-5):360-7. Epub 2002/10/18. doi: 10.1007/s00439-002-0798-z PMID: 12384777.
25. Lunetta KL. Genetic association studies. Circulation. 2008; 118(1):96-101. Epub 2008/07/02. doi: 10.1161/CIRCULATIONAHA.107.700401 118/1/96 [pii]. PMID: 18591452.
26. Tanaka Y, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet. 2011; 20(17):3507-16. Epub 2011/06/11.ddr249 [pii] doi: 10.1093/hmg/ddr249 PMID: 21659334.
27. Maan R, van der Meer AJ, Hansen BE, Feld JJ, Wedemeyer H, Dufour JF, et al. Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. J Hepatol. 2014; 61(3):482-91. Epub 2014/05/02. S0168-8278(14)00284-0 [pii] doi: 10.1016/j.jhep.2014.04.021 PMID: 24780302.
28. Akamatsu S, Hayes CN, Tsuge M, Murakami E, Hiraga N, Abe H, et al. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism. J Viral Hepat. 2014. Epub 2014/06/17. doi: 10.1111/jvh.12275 PMID: 24930407.
29. Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, et al. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. J Hepatol. 2013; 59(4):667-74. Epub 2013/05/28. S0168-8278(13)00348-6 [pii] doi: 10.1016/j.jhep.2013.05.017 PMID: 23707372.
30. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53(2):415-21. Epub 2011/01/20. doi: 10.1002/hep.24058 PMID: 21246582.
31. Aghemo A, Grassi E, Rumi MG, D'Ambrosio R, Galmozzi E, Degasperi E, et al. Limited utility of ITPA deficiency to predict early anemia in HCV patients with advanced fibrosis receiving Telaprevir. PLoS One. 2014; 9(4):e95881. Epub 2014/04/25. doi: 10.1371/journal.pone.0095881 PONE-D-13-48917 [pii]. PMID: 24760000; PubMed Central PMCID: PMC3997406.
32. Boglione L, De Nicolo A, Cusato J, Cariti G, Di Perri G, D'Avolio A. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir. J Viral Hepat. 2014; 21(4):260-3. Epub 2014/03/07. doi: 10.1111/jvh.12170 PMID: 24597694.
33. Asselah T ZS, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, et al. ITPA gene variants predict hemolytic ribavirin induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in sound-C2. J Hepatol. 2013; 58(Suppl. 1):S482.
34. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hezode C, Zeuzem S, et al. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection-a randomized trial. Gastroenterology. 2013; 145(5):1035-44e5. Epub 2013/08/09. S0016-5085(13)01141-4 [pii] doi: 10.1053/j.gastro.2013.07.051 PMID: 23924660.
35. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, et al. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013; 57(3):974-84. Epub 2012/10/20. doi: 10.1002/hep.26096 PMID: 23081753.
36. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013; 368 (20):1867-77. Epub 2013/04/24. doi: 10.1056/NEJMoa1214854 PMID: 23607593.
37. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. N Engl J Med. 2014. Epub 2014/05/06. doi: 10.1056/NEJMoa1316145 PMID: 24795201.